Scientists develop nanorods from aspirin for cataract treatment

     New Delhi, Aug 2 (PTI) Scientists from the Institute of Nano Science and Technology (INST) have developed nanorods from aspirin for treating cataracts in a non-invasive and economical way.
     "This easy to use and low-cost alternative nonsurgical treatment method will benefit patients in developing countries who cannot access expensive cataract treatments and surgeries," according to an official statement.
     The research has been published in the Journal of Materials Chemistry B.
     Cataract is a major form of blindness that occurs when the structure of crystallin proteins that make up the lens in our eyes deteriorates, causing damaged or disorganised proteins to aggregate and form a milky blue or brown layer, which ultimately affects lens transparency.
     Thus, prevention of the formation of these aggregates as well as their destruction in the early stage of disease progression is a major treatment strategy for cataracts, and materials that can carry out this task could make cataract prevention affordable and accessible.
     The scientists from INST, Punjab, an institute under the Department of Science and Technology, have used the anti-aggregation ability of self-build aspirin nanorods as an effective non-invasive small molecule-based nanotherapeutics against cataract.
     Aspirin nanorods prevent the aggregation of crystallin protein and various peptides derived from its fragmentation, which play a crucial role in cataract formation.
     As with aging and under various conditions, the lens protein crystallin aggregates to form opaque structures in the eye lens, which impairs vision and causes cataract.
     The targeted disaggregation of the accumulated alpha-crystallin protein and crystallin derived peptide aggregates in aged and cataractous human lenses are considered as a viable therapeutic strategy for the prevention of cataract formation.
     The aspirin nanorods are produced using the process of molecular self-assembly, which is a low-cost and high-yield technique to generate the aspirin nanorods as compared to the high cost and laborious physical methods generally used for the synthesis of nanoparticles.
     Many natural compounds have already been reported as potential aggregation inhibitors for crystallin aggregation, but the utility of nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin in this direction will open a new paradigm.
     In addition, aspirin nanorods, due to their nano-size, will enhance bio-availability, improve drug loading, and lower toxicity. "Hence, the delivery of the aspirin nanorods as eye drops is going to serve as an effective and viable option to treat cataract non-invasively,” the statement added. PTI PR SMN

(This story has not been edited by THE WEEK and is auto-generated from PTI)